TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06926920: A Phase 1/2, Open-label Study of Sacituzumab Govitecan Administered at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

Sponsor: Gilead Sciences · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$8,364,510

Rescue Site Savings

+$5,537,070

Unlock Full NCT06926920 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06926920 Rescue Dossier →